Join prominent members of the International COVID-19 Network for a 2-part virtual panel where they will present the advantage of exchanging data and their results along detection, outcome prediction and Long-COVID risks and monitoring.

In the current worldwide COVID-19 pandemic situation, fast developments not only in vaccines are needed, but also in analytical technology to detect the infection, predict outcomes during hospitalization and more and more important towards Long COVID. Successful development of diagnostic routines need large number of samples and spectroscopic data generated thereof as well as comprehensive metadata coverage. Initiated by Bruker and under guidance of the Australian National Phenome Center (ANPC) run by Prof. Jeremy Nicholson, a worldwide international COVID Research Network consisting of several institutions* collaborate, using completely standardized NMR procedures producing spectral data, exchangeable and integratabtle across the Network.

Nuclear Magnetic Resonance (NMR) spectroscopy technology is a robust analysis technique that can provide a solution to challenges of COVID-19 diagnosis and prediction based on metabolic changes caused by the virus once RUO results can be transferred into certified routines. The concept of phenoconversion and phenoreversion has been developed to follow these changes upon infection up to recovery. Applying NMR spectroscopy with its unique reproducibility and transferability enables the development of sensitive and specific routines for COVID analysis. This information is vital to develop diagnostic and predictive actions, because NMR can connect metabolic information with systems biology on a personalized basis. Because of these advantages, NMR has the potential for the development of effective health monitoring, allowing early detection and treatment effects.

Key Topics Include:

  • The level of complexity COVID-19 presents for emerging technology applications and scientific concepts
  • How the mass scale of the pandemic encouraged international collaborative efforts to meet the challenges posed by the global outbreak of COVID-19
  • The need for powerful tools, like NMR, to enable research and development for new treatments

Who Should Attend?

This webinar is of particular interest to Researchers in COVID-19, Heads of Clinical Research, Head of Clinical Chemistry, University Hospitals, Medical Universities, Institute for Clinical and Experimental Medicine,  Metabolic Centres, Epidemiologists, and those researching Oncology, Diabetes, Infection, Paediatrics and Cardiology.

Presenters

Jeremy Nicholson, ;PhD, Prof.

Jeremy Nicholson, PhD, Prof.

Pro-Vice Chancellor for Health Sciences
Murdoch University

An internationally-renowned pioneer in metabolic phenotyping and systems medicine, Professor Nicholson is the Pro Vice Chancellor for Health Sciences at Murdoch University and a Clarivate Analytics Highly Cited Researcher who has authored more than 700 peer-reviewed papers on molecular aspects of body systems medicine. A Fellow of the UK Academy of Medical Science, Professor Nicholson comes to WA from Imperial College London where he was the founding director of the MRC-NIHR National Phenome Centre.
Oscar Millet, ;PhD

Oscar Millet, PhD

Principal Investigator
Precision Medicine and Metabolism
CIC bioGUNE

Dr. Oscar Millet is the group leader of the Precision Medicine and Metabolism group of the CIC bioGUNE. His research focuses on the use of nuclear magnetic resonance (NMR) in the study of biologically relevant proteins and enzymes, paying special attention to the metabolic information that can be extracted from biological samples such as serum and urine. He has been awarded the Real Sociedad Española de Química prize (2004), the Spanish NMR group prize (2005), and the Innovation Award of the Basque Government (2018). He is the scientific founder of the spin-off Atlas Molecular Pharma and is the president of the Spanish Chemical Biology Group.
Watch Webinar

Webinar Host

Bruker Corporation

Bruker offers preclinical imaging solutions for a broad spectrum of application fields, such as cancer research, neuroimaging and cardiac disease.

VIEW PROFILE
Bruker Corporation

Additional Content From Bruker Corporation

Related Content